Pancreatic cancer
Breakthrough treatment for pancreatic cancer doubles survival rates
January 25, 2017Research and Development CRUK, Cancer Research UK, Pancreatic cancer
Research led by Liverpool University and funded by Cancer Research UK has shown that a combination treatment of two off-patent …
Shire receives positive EU opinion for pancreatic cancer drug
July 25, 2016Research and Development, Sales and Marketing CHMP, EU, Pancreatic cancer, Shire
Shire has announced that the EU regulator’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion …
Aduro’s pancreatic cancer immunotherapy fails Phase II trials; shares plunge
May 17, 2016Manufacturing and Production, Research and Development, Sales and Marketing Aduro Biotech, Pancreatic cancer, Stock, drug trial, markets
Shares in Aduro Biotech (Nasdaq: ADRO) dropped to closed down over 16% after the company said mid-stage trials of its …
Incyte to stop Jakafi pancreatic, colorectal cancer drug trials
February 11, 2016Research and Development Incyte, Jakafi, Jakavi, Novartis, Pancreatic cancer, colorectal cancer
Incyte said today that it is terminating its JANUS clinical trial programme testing blood cancer drug Jakafi in solid tumours …
Late-stage failure for Merck and Threshold cancer drug
December 7, 2015Research and Development, Sales and Marketing Merck, Pancreatic cancer, Threshold Pharmaceuticals, evofosfamide, late-stage failure, phase III, sarcoma
Merck and its development partner Threshold Pharmaceuticals say they will not pursue regulatory approval for evofosfamide in advanced soft tissue …
Scientists make possible pancreatic cancer discovery
November 18, 2015Research and Development Pancreatic cancer
Cancer researchers say they have discovered a potential new method of treatment for pancreatic cancer that could improve survival rates. …
FDA approves new therapy for pancreatic cancer
October 30, 2015Medical Communications, Sales and Marketing FDA, Pancreatic cancer
The FDA has approved drug a pancreatic cancer drug, Onivyde, which has produced significant overall survival rates in an international …
NICE says Celgene’s Abraxane is ‘too expensive for pancreatic cancer’
September 17, 2015Sales and Marketing Abraxane, Celgene, NICE, Pancreatic cancer
NICE has decided not to recommend Abraxane (nab-paclitaxel) by Celgene in combination with gemcitabine for adults with metastatic pancreatic cancer.In …
Cancer Research UK and Astellas announce partnership
August 8, 2014Medical Communications, Research and Development, Sales and Marketing Astellas, CRUK, Canncer, Pancreatic cancer
Cancer Research UK and its commercial arm, Cancer Research Technology (CRT) have announced they are joining forces with Astellas in …
Afinitor expands European licence
September 5, 2011Sales and Marketing Afinitor, Novartis, Pancreatic cancer
Novartis’ Afinitor has made further strides in the EU with an approval for use in patients with advanced pancreatic neuroendocrine …
Amgen aims for oncology expansion and a wider denosumab license
January 12, 2011Research and Development AMG- 479, AMG-386, Amgen, Cancer, Pancreatic cancer, denosumab, motasenib
Amgen is seeking to increase the use of its bone drug denosumab and further its reach into the oncology market, …
